SINCO PHARMA6833.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, SINCO PHARMA (6833.HK) trades at a P/E of 8.40x, P/B of 0.36x, P/S of 0.13x, and a dividend yield of 1.16%.
Longitudinal percentile comparison: P/E sits at the 27th percentile over the trailing 10Y window (vs. 23rd percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/S sits at the 6th percentile over the trailing 10Y window (vs. 22nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 22nd percentile within its industry and the 39th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.16%, ranking at the 80th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 25.8 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. SINCO PHARMA operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 6833 · SEHK: 6833 · 6833
Want the full picture on whether SINCO PHARMA (6833.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 8.40 | ||||||
| P/B (MRQ) | 0.36 | ||||||
| P/S (TTM) | 0.13 | ||||||
| Dividend Yield | 1.16% | ||||||
| Buyback + Div Yield | 1.16% |